World Lung 2024 – backing for ifinatamab’s pivotal move
The mid-stage Ideate-Lung01 study bears out ifinatamab-dxd’s efficacy in small-cell lung cancer.
The mid-stage Ideate-Lung01 study bears out ifinatamab-dxd’s efficacy in small-cell lung cancer.
Five years after AbbVie pulled the plug on rova-T, DLL3 comes under the spotlight again.
Fears that Adriatic’s statistical survival wins would be clinically marginal haven’t materialised.
SEZ6 looks promising but early, while questions remain around toxicity with AbbVie's cMet ADCs.
The $1bn price tag for the preclinical Mariana Oncology shows that competition for assets in this space is fierce.
Abstract titles reveal some of ASCO’s key datasets.
The group was a first mover in stage III NSCLC, and now it hopes to repeat the trick in SCLC.